Zytiga | malecare.org

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]

By Malecare|2016-06-14T09:24:42-04:00June 14th, 2016|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|0 Comments

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

By Malecare|2020-02-04T11:38:56-05:00May 12th, 2016|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, Drugs & Treatments, enzalutamide, prognostic tools, PSA, Research, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|1 Comment

Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting

Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very significant concerns about Zytiga’s efficacy when used prior to chemotherapy. They reviewed the clinical records of men with metastatic castrate [...]

By Malecare|2017-10-19T10:46:35-04:00April 1st, 2016|abiraterone acetate, Advanced Prostate Cancer, Asia, Clinical Trials & Research, Disease Progression, Drugs & Treatments, Research, Uncategorized, Understanding Advanced Prostate Cancer, Zytiga|2 Comments

UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy

In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior recommendation was not to approve Zytiga. TAccording to NICE their decision to change their December 2015 recommendation follows the submission [...]

By Malecare|2017-10-19T10:46:36-04:00March 28th, 2016|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, NICE, Politics of Cancer, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|0 Comments

Xtandi Vs Zytiga

The phase III trials for both Xtandi and Zytiga were similar. Both trials investigated men who progressed or died against placebo. Only 14% of men taking Xtandi during the trial progressed or died compared to 40% of the men in the placebo group. In the phase III trial of Zytiga 28% of the men [...]

By Malecare|2019-08-16T09:30:57-04:00March 18th, 2016|Advanced Prostate Cancer, Clinical Trials, Clinical Trials & Research, Disease Progression, Drugs & Treatments, enzalutamide, General Information, Survival, Uncategorized, Xtandi, Zytiga|8 Comments